Rapidly reversed thrombin binding oligonucleotide anticoagulants

Details Rapidly reversed thrombin binding oligonucleotide anticoagulants Rapidly reversed thrombin binding oligonucleotide anticoagulants

1998-01-14

1999-03-16

LeGuyader, John L.

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

435 13, 435 911, 536 231, C12Q 168, C12Q 156, C07H 2104

Patent

active

058828702

ABSTRACT:
The present invention relates to a system for the reversible anticoagulation of blood utilizing a nucleic acid ligand which binds thrombin and a reversing agent which has greater affinity for the nucleic acid ligand than does thrombin. When used with a blood sample, the nucleic acid ligand binds thrombin, preventing it from converting fibrinogen to fibrin, and thus anticoagulating the blood. Subsequently, the reversing agent may be added to the anticoagulated blood sample, and by competitive binding, replaces thrombin bound to the ligand, thus freeing the thrombin to convert fibrinogen to fibrin and allowing the blood to coagulate.

REFERENCES:
patent: 5476766 (1995-12-01), Gold et al.
patent: 5668265 (1997-09-01), Nadeau
DeAnda et al. Ann. Thorac. Surg. 58, 344-50 (1994).
Kubik, Mark F. et al., Nucleic Acids Research; 22, 13, pp. 2619-2626 (1994).
Bock, Louis C. et al., Nature; 355 pp. 564-566 (1992).

Affiliated with

Also associated with

Rating

Rapidly reversed thrombin binding oligonucleotide anticoagulants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rapidly reversed thrombin binding oligonucleotide anticoagulants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapidly reversed thrombin binding oligonucleotide anticoagulants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-816418